Equities research analysts expect Quanterix Corp (NASDAQ:QTRX) to report earnings of ($0.40) per share for the current quarter, Zacks reports. Three analysts have provided estimates for Quanterix’s earnings, with the highest EPS estimate coming in at ($0.36) and the lowest estimate coming in at ($0.44). Quanterix posted earnings per share of ($0.33) during the same quarter last year, which would suggest a negative year-over-year growth rate of 21.2%. The company is scheduled to issue its next quarterly earnings report after the market closes on Thursday, May 9th.
According to Zacks, analysts expect that Quanterix will report full year earnings of ($1.56) per share for the current financial year, with EPS estimates ranging from ($1.59) to ($1.53). For the next year, analysts anticipate that the firm will report earnings of ($0.80) per share, with EPS estimates ranging from ($1.02) to ($0.57). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that cover Quanterix.
Quanterix (NASDAQ:QTRX) last posted its quarterly earnings data on Monday, March 18th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.17). Quanterix had a negative return on equity of 76.62% and a negative net margin of 79.48%. The company had revenue of $10.88 million for the quarter, compared to analysts’ expectations of $9.69 million.
Shares of NASDAQ:QTRX opened at $22.72 on Friday. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.10 and a quick ratio of 2.95. The stock has a market cap of $510.90 million, a price-to-earnings ratio of -15.89 and a beta of 1.28. Quanterix has a twelve month low of $13.00 and a twelve month high of $26.48.
In related news, Chairman E Kevin Hrusovsky sold 1,903 shares of Quanterix stock in a transaction on Friday, March 1st. The shares were sold at an average price of $25.00, for a total value of $47,575.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP David C. Duffy sold 1,277 shares of Quanterix stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $20.78, for a total transaction of $26,536.06. The disclosure for this sale can be found here. Insiders have sold 14,498 shares of company stock worth $337,811 over the last three months. Insiders own 31.60% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Gilder Gagnon Howe & Co. LLC increased its position in shares of Quanterix by 0.5% during the 1st quarter. Gilder Gagnon Howe & Co. LLC now owns 986,587 shares of the company’s stock valued at $25,484,000 after purchasing an additional 4,430 shares during the last quarter. Morgan Stanley increased its holdings in Quanterix by 525.7% in the 1st quarter. Morgan Stanley now owns 105,998 shares of the company’s stock worth $2,738,000 after acquiring an additional 89,056 shares in the last quarter. Macquarie Group Ltd. increased its holdings in Quanterix by 303.5% in the 1st quarter. Macquarie Group Ltd. now owns 22,044 shares of the company’s stock worth $569,000 after acquiring an additional 16,581 shares in the last quarter. SEI Investments Co purchased a new stake in Quanterix in the 1st quarter worth approximately $819,000. Finally, Geode Capital Management LLC increased its holdings in Quanterix by 37.4% in the 1st quarter. Geode Capital Management LLC now owns 125,882 shares of the company’s stock worth $3,251,000 after acquiring an additional 34,292 shares in the last quarter. 51.76% of the stock is currently owned by institutional investors.
Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Simoa HD-1 instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids.
Read More: Why is total return important?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.